What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?

. 2022 Aug 16;99(7 Suppl 1):61-67.

doi: 10.1212/WNL.0000000000200786.

Affiliations

¹ From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT. jseibyl@indd.org.
² From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT.

John Peter Seibyl et al. Neurology. 2022.

. 2022 Aug 16;99(7 Suppl 1):61-67.

doi: 10.1212/WNL.0000000000200786.

¹ From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT. jseibyl@indd.org.
² From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT.

No abstract available

Cited by

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.
Katunina EA, Blokhin V, Nodel MR, Pavlova EN, Kalinkin AL, Kucheryanu VG, Alekperova L, Selikhova MV, Martynov MY, Ugrumov MV. Katunina EA, et al. Int J Mol Sci. 2023 Jan 17;24(3):1842. doi: 10.3390/ijms24031842. Int J Mol Sci. 2023. PMID: 36768161 Free PMC article.